Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Clin Lab ; 62(6): 1109-16, 2016.
Article in English | MEDLINE | ID: mdl-27468573

ABSTRACT

BACKGROUND: Proteomic candidate biomarkers for systemic sclerosis (Ssc) useful for appropriate patient evaluation and follow-up were identified in mass-spectrometry studies; however, most of these biomarkers were not evaluated and confirmed on independent patient samples. Up-regulation of reticulocalbin 1 (RCN1) and reticulocalbin 3 (RCN3) in the dermal fibroblast secretome originating from Ssc patients was previously described. The aim of the study was to evaluate circulating RCN1 and RCN3 as candidate biomarkers for Ssc clinical expression. METHODS: 40 consecutive Ssc patients and 20 gender and age matched controls were included. Serum RCN1 and RCN3 was evaluated using commercial ELISA kits. RESULTS: Serum RCN1 and RCN3 were not statistically significant different between Ssc patients and healthy controls. Serum RCN1 and RCN3 were correlated in both Ssc and healthy control groups (p < 0.001). Serum RCN1 was positively correlated with Ssc disease activity score (EUSTAR, p = 0.02) and remained associated with EUSTAR after adjusting for disease duration in multivariate analysis. 6 Ssc patients (15%) had elevated RCN1 values compared to reference values obtained from healthy control samples. These patients had higher prevalence of digital ulcers, higher disease activity scores, and tended to have esophageal hypomotility, calcinosis, telangiectasia, and diffuse Ssc subtype. CONCLUSIONS: RCN1 and RCN3 expression was not statistically significantly different to healthy controls. However, RCN1 was associated with disease activity score and could be used as a stratification biomarker for Ssc patients, as patients with high RCN1 shared a particular disease pattern.


Subject(s)
Calcium-Binding Proteins/blood , Scleroderma, Systemic/blood , Adult , Aged , Biomarkers/blood , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Scleroderma, Systemic/diagnosis , Severity of Illness Index
2.
Biomarkers ; 21(2): 102-14, 2016.
Article in English | MEDLINE | ID: mdl-26632636

ABSTRACT

CONTEXT: Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver which is accompanied by a series of metabolic deregulations. There are sustained research efforts focusing upon biomarker discovery for NAFLD diagnosis and its prognosis in order investigate and follow-up patients as minimally invasive as possible. OBJECTIVE: The objective of this study is to critically review proteomic studies that used mass spectrometry techniques and summarize relevant proteomic NAFLD candidate biomarkers. METHODS: Medline and Embase databases were searched from inception to December 2014. RESULTS: A final number of 22 records were included that identified 251 candidate proteomic biomarkers. Thirty-three biomarkers were confirmed - 14 were found in liver samples, 21 in serum samples, and two from both serum and liver samples. CONCLUSION: Some of the biomarkers identified have already been extensively studied regarding their diagnostic and prognostic capacity. However, there are also more potential biomarkers that still need to be addressed in future studies.


Subject(s)
Biomarkers/analysis , Mass Spectrometry/methods , Non-alcoholic Fatty Liver Disease/metabolism , Proteome/analysis , Proteomics/methods , Biomarkers/blood , Humans , Liver/metabolism , Liver/pathology , Non-alcoholic Fatty Liver Disease/blood , Prognosis
3.
J Clin Lab Anal ; 30(5): 368-73, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26331941

ABSTRACT

BACKGROUND: Systemic sclerosis (Ssc) is an autoimmune disease characterized by vascular alterations of small arteries and microvessels with subsequent tissue fibrosis. Endocan is expressed by endothelial cells and associated with endothelial dysfunction; therefore it could be a potential biomarker for Ssc patients. METHODS: Twenty-one Ssc patients and 20 sex- and age-matched healthy controls were recruited for the study. Serum endocan levels were determined using ELISA method in all patients and controls. RESULTS: Serum endocan levels were superior in Ssc patients (median 2.53 (1.10-7 ng/ml)) compared with controls (0.79 (0-2 ng/ml), P < 0.05). Higher serum endocan expression was seen in diffuse Ssc subset and associated with the presence of digital ulcers and daily Raynaud's phenomenon (P < 0.05). Higher serum endocan levels were associated with a modified Rodnan skin score >14 and longer disease duration (P < 0.05). Values of areas under the receiver operating curves showed that serum endocan had good discriminative power for Ssc diagnosis, differentiating diffuse from limited subset type and differentiating patients with modified Rodnan skin score above and under 14 (area under curve: 0.94, 0.81, 0.75, respectively). CONCLUSION: The results of this pilot study suggest endocan as a potential biomarker for microvascular manifestations and complications in Ssc patients. These encouraging results could promote future prospective studies in order to determine the exact role played by endocan as a biomarker for Ssc.


Subject(s)
Neoplasm Proteins/blood , Proteoglycans/blood , Scleroderma, Systemic/blood , Adult , Aged , Autoantibodies/blood , Biomarkers/blood , Case-Control Studies , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Male , Middle Aged , Pilot Projects , Statistics, Nonparametric
4.
Rom J Intern Med ; 53(1): 44-9, 2015.
Article in English | MEDLINE | ID: mdl-26076560

ABSTRACT

BACKGROUND: Systemic sclerosis (Ssc) is an autoimmune disease characterized by cutaneous and visceral fibrosis and its pathogenesis is incompletely understood. T helper cells are key regulators of the immune response and they seem to be involved in Ssc clinical manifestations. The aim of the study is to determine key cytokines secreted by Th1 (IFN-γ), Th2 (IL-6) and Th17 (IL-17) in Ssc patients and correlate them with specific manifestations of Ssc patients. MATERIAL AND METHODS: 35 consecutive Ssc patients and 20 age and sex matched controls were recruited. Serum IL-17, IFN-γ and IL-6 were determined using ELISA method. RESULTS: Serum IL-17 and IL-6 levels were not significantly different in Ssc patients and controls. Serum IFN-γ levels were higher in Ssc patients when compared to controls. Higher serum IFN-γ levels associated with pulmonary hypertension. After adjusting for gender and age, IL-17 levels remained independently associated with some clinical manifestations of Ssc patients (telangiectasia and high activity score of Ssc). CONCLUSION: Th17 and Th1 cell responses are active in Ssc patients as their cytokines associated with higher disease activity scores and pulmonary manifestations. Th17 and Th1 specific activity and homing within Ssc patients still needs to be defined and determined in order to target them as potential future therapeutic targets in Ssc patients.


Subject(s)
Interferon-gamma/blood , Interleukin-17/blood , Interleukin-6/blood , Scleroderma, Systemic/blood , Adult , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged
5.
Scand J Clin Lab Invest ; 75(6): 476-81, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26067612

ABSTRACT

Some systemic sclerosis (Ssc) patients express antiphospholipid antibodies and their percentage varies within studies in the literature. The particular role of these antibodies in clinical manifestations of Ssc is still unknown. The aim of the study was to examine an extended panel of antiphospholipid antibodies in Ssc patients who did not have any clinical features of antiphospholipid antibody syndrome. A cross-sectional study was designed and 36 consecutive patients with Ssc were recruited. A relatively high proportion of patients (14 patients - 38.9%) had antiphospholipid antibody presence. Most Ssc patients (11 patients - 30.6%) had IgM anti phosphatidyl ethanolamine antibodies. Serum IgM anti phosphatidyl ethanolamine antibodies, IgM anti prothrombin and IgG anti ß2 glycoprotein 1 antibodies were associated with low complement levels in Ssc patients. In multivariate analysis, only serum IgM anti phosphatidyl ethanolamine antibodies concentration and serum IgG anti ß2 glycoprotein 1 antibodies concentration were independently associated with hypocomplementemia after adjusting for age and gender. No other correlations with Ssc clinical characteristics were found. In conclusion, antiphospholipid antibodies are present in a large proportion of Ssc patients who do not have clinical features or a history of antiphospholipid antibodies. IgM anti phosphatidyl ethanolamine antibodies seem to be more frequent and the dominant antiphospholipid antibody type in the group recruited from the Romanian Ssc population.


Subject(s)
Antibodies, Antiphospholipid/blood , Complement System Proteins/analysis , Phosphatidylethanolamines/immunology , Scleroderma, Systemic/immunology , Aged , Antibodies, Anti-Idiotypic/blood , Antiphospholipid Syndrome/etiology , Cross-Sectional Studies , Female , Humans , Immunoglobulin M/blood , Lupus Coagulation Inhibitor/blood , Male , Middle Aged , Prothrombin , Romania , Scleroderma, Systemic/etiology , beta 2-Glycoprotein I/immunology
6.
Biomarkers ; 19(5): 345-55, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24831309

ABSTRACT

CONTEXT: Systemic sclerosis (SSc) is an autoimmune disease with incompletely known physiopathology. There is a great challenge to predict its course and therapeutic response using biomarkers. OBJECTIVE: To critically review proteomic biomarkers discovered from biological specimens from systemic sclerosis patients using mass spectrometry technologies. METHODS: Medline and Embase databases were searched in February 2014. RESULTS: Out of the 199 records retrieved, a total of 20 records were included, identifying 116 candidate proteomic biomarkers. CONCLUSION: Research in SSc proteomic biomarkers should focus on biomarker validation, as there are valuable mass-spectrometry proteomics studies in the literature.


Subject(s)
Biomarkers/metabolism , Mass Spectrometry/methods , Proteome/metabolism , Proteomics/methods , Scleroderma, Systemic/metabolism , Humans , Reproducibility of Results , Scleroderma, Systemic/diagnosis , Sensitivity and Specificity
7.
Clin Lab ; 60(3): 505-10, 2014.
Article in English | MEDLINE | ID: mdl-24697130

ABSTRACT

BACKGROUND: Endocan is a marker of angiogenesis previously studied in various types of cancer and inflammatory conditions. Its expression is influenced by vascular endothelial growth factor A (VEGF A) and tumor necrosis factor alpha (TNF alpha), cytokines involved in pathogenetic pathways in inflammatory bowel disease (IBD). The aim of this study was to determine whether serum endocan levels were increased in IBD patients. METHODS: We conducted an exploratory pilot study. Serum endocan levels were determined in a group of 33 consecutive IBD patients from an observational cohort study ongoing at Colentina Hospital and compared to levels determined in two control groups: healthy controls and stage IV cancer patients. RESULTS: Endocan levels were significantly higher in the IBD group as compared to both healthy controls (p < 0.001) and cancer patients (p < 0.01). There was no correlation found between endocan levels and disease activity as assessed by clinical or endoscopical activity scores. CONCLUSIONS: There is a potential role for endocan in future biomarker studies in IBD patients.


Subject(s)
Inflammatory Bowel Diseases/blood , Neoplasm Proteins/blood , Proteoglycans/blood , Adult , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Pilot Projects
8.
Rom J Intern Med ; 50(1): 13-8, 2012.
Article in English | MEDLINE | ID: mdl-22788089

ABSTRACT

Hepatitis C virus (HCV) is one of the most important etiologic agents of postransfusional hepatitis and a common cause of chronic hepatitis, cirrhosis and hepatocarcinoma. T helper (Th)17 cells are a newly discovered Th cell subset with implications in both host defense and autoimmunity. Th17 implications in chronic HCV infection are not well characterized. Given the important role in multiple other immune and inflammatory conditions, they are of obvious interest. Specific HCV-Th17 cells are implicated in immune response modulation, correlated with fibrosis severity and intrahepatic inflammatory status. Serum IL-17 levels are higher in chronic HCV infected patients and Th17 cytokines are modulated within the therapeutic response at anti-viral treatment. However, novel intriguing data indicate that Th17 boost could be associated with spontaneous HCV clearance. It is possible that Th17 could play a dual role (both beneficial and harmful) and that an unbalance of regulating factors (chemokines, transcription factors, receptor expression, etc.) rather than the lymphocyte itself could tip the Th17 immune response one way or another. The role of Th17 cells in host anti HCV defense is beginning to emerge and one has to focus upon its potential beneficial aspects and not only on its destructive potential.


Subject(s)
Hepatitis C, Chronic/immunology , Hepatitis C/immunology , Interleukin-17/immunology , Th17 Cells/immunology , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Humans , Liver Transplantation
SELECTION OF CITATIONS
SEARCH DETAIL
...